查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1819858

2025 年至 2033 年骨科生物製品市場報告（按產品、類型、應用、最終用戶和地區）

Orthobiologics Market Report by Product, Type, Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球骨科生物製品市場規模達63億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到94億美元，2025-2033年期間的複合年成長率（CAGR）為4.31%。北美目前是最大的市場，這得益於該地區肌肉骨骼疾病的高發病率、老年人口的不斷成長以及高強度體力活動和體育運動的普遍趨勢。微創手術（MIS）需求的不斷成長、生物治療的持續進步以及骨移植、幹細胞治療和再生醫學領域的持續技術創新，是推動市場擴張的一些關鍵因素。

主導部分：

  • 產品：黏液補充產品因其在治療骨關節炎（尤其是膝關節骨關節炎）方面的有效性而佔據了大部分市場佔有率。
  • 類型：膝蓋佔最大佔有率，因為膝蓋退化性疾病（如骨關節炎）和韌帶撕裂、軟骨損傷等損傷的發生率很高。
  • 應用：骨關節炎和退化性關節炎由於其廣泛的流行和影響而佔據了主要的細分市場。
  • 最終用戶：醫院和門診中心憑藉其全面的診斷和治療能力在市場上佔據明顯的主導地位。
  • 地區：北美是市場領導者，該地區肌肉骨骼疾病（如骨關節炎）患病率高，老年人口不斷擴大，並且普遍存在高強度體力活動和運動的趨勢。

關鍵參與者：

  • 市場領先的公司包括 Arthrex Inc、Globus Medical Inc.、Integra LifeSciences、Johnson & Johnson、Medline Industries Inc.、Medtronic plc、NuVasive Inc、Orthofix Medical Inc.、Smith & Nephew plc、Stryker Corporation、Terumo Corporation、Wright Medical Group NV、Zimmer Biomet 等。

市場成長的關鍵驅動力：

  • 人口老化：全球老齡人口的成長推動了對骨科生物製劑的需求，老年人口患骨關節炎和關節退化等肌肉骨骼疾病的風險更高，需要複雜的治療。
  • 醫療技術的進步：幹細胞療法、富血小板血漿 (PRP) 和組織工程方法等醫療技術的發展正在提高治療的有效性和安全性，從而拓寬其臨床用途。
  • 微創療法：與傳統手術方法相比，微創療法具有恢復速度更快、併發症更少等特點，因此對微創療法的需求日益成長，推動了骨生物學治療在關節再生和修復中的應用。
  • 運動傷害和活躍生活方式的增加：越來越多的人參與體育運動和鍛煉，加上對健身的日益重視，導致運動相關傷害的增加，進一步催化了對成功的再生療法的需求。
  • 報銷政策和監管支持：更大的保險覆蓋範圍和支持性的監管環境有助於為患者提供骨生物學治療，從而刺激市場成長。

未來展望：

  • 強勁的成長前景：受持續的技術創新、非手術治療意識的提高以及越來越多的人選擇傳統手術的替代方案的推動，骨科生物製品市場預計將穩步成長。
  • 市場演變：市場可能會從小眾、昂貴的治療方法轉向針對不同肌肉骨骼疾病的更實惠、主流的選擇，從而使骨科生物學成為骨科的主流選擇。

隨著各種趨勢持續影響肌肉骨骼治療的模式，骨科生物製劑市場正在改變。在醫療保健計劃、教育活動以及網路資訊獲取管道不斷拓展的推動下，人們對肌肉骨骼健康和骨科生物製劑治療優勢的認知正在不斷提高。隨著人們越來越了解生物療法在治療慢性疼痛、關節退化和軟組織創傷方面的作用，對此類治療的需求也日益成長。醫生們也不斷學習骨科生物製劑的最新進展，以便更好地告知患者可供選擇的治療方案。隨著知名運動員和團隊擴大尋求生物療法進行復健治療，職業和業餘運動員對骨科生物製劑的接觸也日益增多，這推動了骨科生物製劑的普及。隨著知識的傳播，越來越多的患者預約生物療法諮詢，推動了各類患者對骨科生物製劑的需求。

骨科生物學市場趨勢：

非手術治療的需求不斷成長

由於對非侵入性治療的需求不斷成長，骨科生物製劑市場正經歷著巨大的成長。如今，越來越多的患者選擇微創 (MI) 手術，以加快康復速度並降低併發症風險。富血小板血漿 (PRP) 和幹細胞療法等骨科生物製劑正在為肌肉骨骼損傷、骨關節炎和關節退化等傳統手術提供成功的替代方案。隨著越來越多的患者尋求長期住院和康復的替代方案，醫生擴大使用骨科生物製劑治療來滿足這些需求。人們對生物療法優勢的認知不斷提高，以及越來越多的臨床證據表明生物療法是組織修復和再生的有效方法，正在推動非侵入性治療的應用。這一趨勢可能會繼續推動市場成長，因為患者和醫療保健系統都在擴大尋求侵入性更小、更具成本效益和更有效的治療方式。 IMARC Group預測，到2033年全球微創手術市場規模預計將達到949億美元。

再生醫學的進展

再生醫學的持續發展推動著骨科生物製品產業的發展。技術和研究的進步不斷提升著幹細胞療法、透明質酸注射和富血小板血漿 (PRP) 等療法的療效。這些發展使得骨科生物製品療法能夠再生或修復受損組織，加速復原速度，並減少對大型外科手術的需求。此外，組織工程和生物製品配方的進步也提高了此類治療的療效和安全性，並為肌肉骨骼疾病的治療提供了機會。隨著再生醫學的不斷進步，骨科生物製品治療變得越來越成熟和受歡迎，並越來越受到醫療保健提供者和患者的青睞。再生醫學領域的不斷進步正大大擴展骨科生物製品的臨床應用，為肌腱損傷、軟骨損傷以及慢性關節疼痛等損傷提供新的治療方法。 2025年，布里奇波特大學（UB）與著名的TulsiHub研究所合作，在快速發展的再生醫學領域推出了一項創新證書課程。該課程為期12週，經CE認證，旨在培養醫療保健專業人員和學生掌握再生療法領域的頂級技能，畢業生畢業後可獲得種子資金，開設自己的診所。獲得資金後，醫療保健提供者能夠將這些先進的治療方法直接提供給當地患者。首批三門課程的週末課程已於6月開課，這三門課程分別是「綜合再生皮膚病學和骨科輸液護理」、「再生皮膚病學和美學」以及「再生骨科和綜合關節護理」。

日益成長的運動和健身趨勢

體育運動和健身活動的日益普及，大大促進了市場的成長。隨著人們參與體育鍛煉，扭傷、撕裂和骨折等運動相關傷害的發生率也在上升。越來越多的運動員和身體活躍人士選擇骨科生物療法，以加速康復、減輕疼痛並增強功能。這些療法，包括富血小板血漿 (PRP) 注射和幹細胞療法，目前正被用於治療軟組織損傷、軟骨損傷和關節疾病。對更快康復和更佳運動表現的需求，推動著職業運動員和業餘健身愛好者紛紛採用骨科生物療法。運動和健身仍然是全球健康生活方式的核心，骨科生物療法市場正順應這一潮流，提供尖端高效的肌肉骨骼損傷治療方案，推動其擴張並更廣泛地融入醫療保健市場。根據 Healio 在 2024 年發表的一篇文章，預計到 2040 年，65 歲以上患者的骨科相關運動傷害將增加 123%，並且可能超過骨科醫生的數量。

骨科生物學市場成長動力：

更加重視個人化醫療

隨著個人化醫療日益受到重視，骨科生物製劑市場正經歷快速成長。基因研究和診斷方法的改進使醫生能夠根據患者的獨特需求量身定做治療方案。對於肌肉骨骼疾病，客製化的骨科生物製劑療法正在根據患者的基因組成、損傷類型和整體健康狀況等變數進行開發，以最大限度地促進康復。透過為患者提供個人化的生物製劑療法（包括幹細胞療法和PRP注射），這些療法在刺激組織再生和改善患者預後方面變得越來越有效。生物標記發現和標靶治療方法的進展也促進了個人化醫療的發展，進一步提高了骨科生物製劑療法的準確性和有效性。

擴大報銷範圍和法規核准

日益擴大的醫保覆蓋範圍和更積極的法規核准極大地推動了骨科生物製品市場的發展。越來越多的國家將生物製品療法納入醫療保險計劃，這提高了患者獲得先進療法的可及性。醫療體係也越來越認可骨科生物製品治療的長期成本效益，因為它能夠最大限度地減少昂貴的手術和漫長的康復期。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構正在批准新的骨科生物製品產品，這進一步增強了市場信心。隨著醫保報銷政策的包容性增強和對再生療法的支持力度加大，越來越多的患者能夠獲得這些治療，從而推動了再生療法的廣泛應用。醫保報銷範圍的擴大和監管部門的認可，使得骨科生物製品對醫療服務提供者和患者都更具經濟永續性，從而促進了市場的擴張。

肌肉骨骼和關節健康意識的提高

人們對關節和肌肉骨骼健康的認知日益增強，推動了對骨科生物製劑的需求。隨著越來越多的人認知到終生保持關節健康的重要性，人們對促進組織修復、減輕疼痛和改善活動能力的治療方法的興趣日益濃厚。公共教育活動和教育計畫正在逐步提高人們對肌肉骨骼疾病（包括關節炎和肌腱損傷）以及骨科生物製劑療法前景的認知。這種認知的提高促使患者尋求傳統手術介入的替代方案，從而導致PRP注射和幹細胞療法等生物製劑治療的應用日益廣泛。此外，隨著世界人口老化，對治療慢性關節疾病的有效且微創療法的需求不斷成長。因此，對關節健康的日益關注正在推動市場成長。

骨科生物學市場細分：

按產品分類：

  • 去礦骨基質
  • 同種異體移植
  • 骨形態發生蛋白
  • 黏液補充產品
  • 合成骨替代品
  • 其他

黏液補充劑產品佔據大部分市場佔有率

根據骨科生物製劑市場研究報告，黏彈性補充劑產品因其在治療骨關節炎（尤其是膝關節骨關節炎）方面的有效性而佔據市場主導地位。這些主要由透明質酸製成的物質被注射到關節中，起到緩衝和潤滑的作用，從而最大限度地減輕不適並增強關節活動度。由於骨關節炎發生率高，尤其是在老年人口中，對​​黏彈性補充劑等非手術和微創治療方案的需求很高。此外，黏彈性補充劑可以緩解疼痛，且無需承擔關節置換手術帶來的重大風險或恢復時間。因此，其便捷的給藥方式、對非侵入性治療的日益青睞以及對黏彈性補充劑益處的日益認知，共同推動了骨科生物製劑需求的成長。

按類型分列：

  • 膝蓋
  • 踝
  • 時髦的
  • 腕部和肩部
  • 脊椎
  • 其他

膝關節佔據業界最大佔有率

膝關節退化性疾病（如骨關節炎）以及韌帶撕裂和軟骨損傷等損傷的高發性是推動骨科生物製劑需求的另一個關鍵因素。膝關節作為負重關節，隨著時間的推移特別容易磨損，導致劇烈疼痛和活動受限。骨科生物製劑治療，包括黏液補充療法和再生療法，常用於緩解膝關節疾病症狀並改善功能。老年人和運動員膝關節疾病的盛行率較高，加上骨科生物製劑介入措施在減輕疼痛和促進癒合方面的有效性，正在推動市場需求。

按應用分類：

  • 骨關節炎和退化性關節炎
  • 脊椎融合
  • 骨折恢復
  • 軟組織損傷
  • 顎面和牙科應用

骨關節炎和退化性關節炎是主要的市場區隔

根據骨科生物製劑市場概況，骨關節炎和退化性關節炎因其廣泛的盛行率和影響而成為主要的細分市場。這些疾病的特徵是關節軟骨逐漸受損，導致疼痛、僵硬和功能受損，尤其是在膝蓋和臀部等負重關節。隨著全球人口老化，越來越多的人出現與年齡相關的關節問題，對有效治療的需求也日益成長。骨科生物製劑解決方案，例如黏液補充療法和再生療法，提供了非手術治療方案來控制症狀、改善活動能力並提升生活品質。它們能夠解決關節退化的根本原因，再加上人們對微創手術（MIS）日益成長的偏好，正在推動骨科生物製劑市場的收入成長。

按最終用戶分類：

  • 醫院及門診中心
  • 研究與學術機構
  • 牙科診所和設施
  • 骨科診所

醫院和門診中心在市場上佔據明顯主導地位

醫院和門診中心憑藉其全面的診斷和治療能力，成為最大的終端使用者群體。這些機構配備了先進的影像和外科技術，能夠精準實施骨科生物治療，例如注射和再生療法。醫院和門診中心通常提供一系列專科服務，包括骨科手術和康復，並與骨科生物介入無縫銜接。此外，處理複雜病例和提供即時醫療支援的能力增強了這些機構對患者和醫療服務提供者的吸引力。這些機構擁有眾多經驗豐富的醫療專業人員，並且能夠輕鬆獲得尖端治療，這進一步推動了這些機構對骨科生物製劑的需求。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美引領市場，佔據骨科生物製劑最大市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是骨科生物製劑最大的區域市場。

骨科生物製劑市場預測顯示，北美地區憑藉其骨關節炎等肌肉骨骼疾病的高發病率、不斷成長的老年人口以及高強度體力活動和體育運動的普遍趨勢，引領市場。美國和加拿大先進的醫療基礎設施和高標準的醫療服務支持創新骨科生物製劑療法的推廣應用。此外，北美地區擁有許多大型製藥和生技公司，這些公司在研發方面投入大量資金，並推動尖端產品的供應。該地區強大的監管框架和雄厚的醫療保健支出進一步促進了市場成長，使其成為骨科生物製劑應用和利用領域的領導者。

本報告回答的關鍵問題：

  • 到目前為止，全球骨科生物製劑市場表現如何，未來幾年將如何表現？
  • 全球骨科生物學市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球骨科生物學市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家代表最具吸引力的骨生物學市場？
  • 根據產品，市場是如何分類的？
  • 骨科生物製劑市場上最有吸引力的產品是什麼？
  • 根據類型，市場是如何分類的？
  • 骨科生物製品市場中最具吸引力的類型是什麼？
  • 根據應用，市場是如何分類的？
  • 骨科生物製劑市場中最具吸引力的應用是什麼？
  • 根據最終用戶，市場是如何分類的？
  • 骨科生物學市場中最具吸引力的最終用戶是誰？
  • 市場的競爭結構是怎麼樣的？
  • 全球骨科生物學市場的主要參與者/公司有哪些？

本報告回答的關鍵問題：

  • 到目前為止，全球骨科生物製劑市場表現如何，未來幾年將如何表現？
  • 全球骨科生物學市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球骨科生物學市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家代表最具吸引力的骨生物學市場？
  • 根據產品，市場是如何分類的？
  • 骨科生物製劑市場上最有吸引力的產品是什麼？
  • 根據類型，市場是如何分類的？
  • 骨科生物製品市場中最具吸引力的類型是什麼？
  • 根據應用，市場是如何分類的？
  • 骨科生物製劑市場中最具吸引力的應用是什麼？
  • 根據最終用戶，市場是如何分類的？
  • 骨科生物學市場中最具吸引力的最終用戶是誰？
  • 市場的競爭結構是怎麼樣的？
  • 全球骨科生物學市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球骨科生物製劑市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依產品

  • 去礦骨基質
  • 同種異體移植
  • 骨形態發生蛋白
  • 黏液補充產品
  • 合成骨替代品
  • 其他

第7章：市場區隔：依類型

  • 膝蓋
  • 踝
  • 時髦的
  • 腕部和肩部
  • 脊椎
  • 其他

第 8 章：市場區隔：按應用

  • 骨關節炎和退化性關節炎
  • 脊椎融合
  • 骨折恢復
  • 軟組織損傷
  • 顎面和牙科應用

第9章：市場區隔：依最終用戶

  • 醫院及門診中心
  • 研究與學術機構
  • 牙科診所和設施
  • 骨科診所

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Arthrex Inc
    • Globus Medical Inc.
    • Integra LifeSciences
    • Johnson & Johnson
    • Medline Industries Inc.
    • Medtronic plc
    • NuVasive Inc
    • Orthofix Medical Inc.
    • Smith & Nephew plc
    • Stryker Corporation
    • Terumo Corporation
    • Wright Medical Group NV
    • Zimmer Biomet
Product Code: SR112025A4332

The global orthobiologics market size reached USD 6.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.4 Billion by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033. North America currently represents the largest region owing to the high prevalence of musculoskeletal disorders, expanding geriatric population, and widespread trends of engaging in high levels of physical activity and sports. The rising demand for minimally invasive surgeries (MIS), ongoing advancements in biologic treatments, and ongoing technological innovations in bone grafts, stem cell therapy, and regenerative medicine are some of the key factors contributing to the market expansion.

Dominant Segments:

  • Product: Viscosupplementation products account for the majority of the market share owing to their effectiveness in treating osteoarthritis, particularly of the knee.
  • Type: Knee holds the largest share due to the high incidence of degenerative conditions in knees like osteoarthritis and injuries such as ligament tears and cartilage damage.
  • Application: Osteoarthritis and degenerative arthritis represent the leading market segment due to their widespread prevalence and impact.
  • End User: Hospitals and ambulatory centers exhibit a clear dominance in the market due to their comprehensive diagnostic and treatment capabilities.
  • Region: North America leads the market with its high prevalence of musculoskeletal disorders, such as osteoarthritis, expanding geriatric population, and widespread trends of engaging in high levels of physical activity and sports.

Key Players:

  • The leading companies in the market include Arthrex Inc, Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries Inc., Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Smith & Nephew plc, Stryker Corporation, Terumo Corporation, Wright Medical Group N.V., Zimmer Biomet, etc.

Key Drivers of Market Growth:

  • Aging Population: Global growth in the aging population is driving the demand for orthobiologics, with the older population at higher risk of suffering from musculoskeletal ailments like osteoarthritis and joint degeneration that are in need of sophisticated treatment.
  • Advancements in Medical Technology: Growth in medical technologies such as stem cell therapy, platelet-rich plasma (PRP), and tissue-engineering methods is enhancing the efficacy and safety of treatments, hence broadening their clinical uses.
  • Minimally Invasive Therapies: Growing demand for minimally invasive therapies, with their faster recovery rates and reduced complications as compared to conventional surgical approaches, is driving the use of orthobiologic treatments for regeneration and repair of joints.
  • Growing Sports Injuries and Active Lifestyles: Increasing involvement in sports and exercise, combined with the rising focus on fitness, is causing a rise in sports-related injuries, further catalyzing the need for successful regenerative therapies.
  • Reimbursement Policies and Regulatory Support: Greater insurance coverage and supportive regulatory environments are helping to deliver patients to orthobiologic therapies, stimulating market growth.

Future Outlook:

  • Strong Growth Outlook: The market for orthobiologics is expected to grow steadily, driven by continuous technological innovation, rising awareness of non-surgical treatments, and the expanding number of people opting for alternatives to conventional surgery.
  • Market Evolution: The market is likely to see a movement from niche, expensive treatments towards more affordable, mainstream options for different musculoskeletal disorders, thus establishing orthobiologics as an orthopedic mainstream option.

The market for orthobiologics is undergoing changes as different trends continue to influence the landscape of musculoskeletal therapies. Awareness about musculoskeletal well-being and the advantages of treatment with orthobiologics is on a rise, fueled by healthcare initiatives, educational campaigns, and the expanding access to information online. As people learn more about the ability of biologic therapies to treat chronic pain, joint degeneration, and soft tissue trauma, the need for such treatments grows. Doctors are also learning more about the most current advances in orthobiologics so that they can better inform patients about the options available to them. Growing exposure to orthobiologic therapies among professional and amateur athletes is driving popularity, as renowned athletes and teams increasingly seek out biologic treatments for rehabilitation. As knowledge spreads, greater numbers of patients are scheduling consultations regarding biologic therapies, driving demand for orthobiologics in a wide range of patients.

Orthobiologics Market Trends:

Growing Demand for Non-Surgical Treatments

The market for orthobiologics is witnessing tremendous growth because of the escalating demand for non-invasive treatment. More patients are now turning towards minimally invasive (MI) procedures that induce quicker recovery and reduced risk of complications. Orthobiologics like platelet-rich plasma (PRP) and stem cell therapies are offering successful alternatives to conventional surgeries for musculoskeletal injuries, osteoarthritis, and joint degeneration. With more patients looking for alternatives to prolonged hospitalization and rehabilitation, physicians are increasingly using orthobiologic treatment to satisfy these demands. Increased awareness of the advantages of biologic therapy, as well as a growing body of clinical evidence that favors them as an effective method for tissue repair and regeneration, are driving the use of non-invasive treatments. This trend will likely continue to propel the market's growth because patients and healthcare systems alike are increasingly looking for less invasive, more cost-efficient, and more effective modes of treatment. IMARC Group predicts that the global minimally invasive surgery market is projected to attain USD 94.9 Billion by 2033.

Advances in Regenerative Medicine

The orthobiologics industry is being driven by continued developments in regenerative medicine. Advances in technology and research are continuously enhancing the efficacy of treatments such as stem cell therapy, hyaluronic acid injections, and PRP. The developments are allowing orthobiologic therapies to regenerate or restore damaged tissues, expedite recovery, and decrease the demand for extensive surgical procedures. In addition, advances in tissue engineering and formulating biologic products are improving the efficacy and safety of such treatments and providing opportunities for the management of musculoskeletal diseases. With continued progress in regenerative medicine, orthobiologic treatments are becoming more sophisticated and well-liked and are gaining popularity among healthcare providers as well as patients. The progressive advancements in the regenerative medicine space are by far driving the clinical uses of orthobiologics wider, providing novel therapies for injuries like tendon damage and cartilage injury, as well as for chronic joint pain. In 2025, The University of Bridgeport (UB) introduced an innovative certificate program in the fast-developing area of Regenerative Medicine, in partnership with the prestigious TulsiHub Institute. This 12-week, CE-approved program aims to prepare healthcare professionals and students with top-tier skills in regenerative therapies, allowing graduates to obtain seed funding to start their own clinics upon finishing. Funding access enables healthcare providers to deliver these advanced methods straight to patients in their local areas. Weekend classes for the initial three courses like Comprehensive Regenerative Dermatology and Orthopedic Infusion Care, Regenerative Dermatology and Aesthetics, and Regenerative Orthopedic and Integrative Joint Care started from June.

Growing Sports and Fitness Trends

The increasing popularity of sports and exercise activities is contributing significantly to the growth of the market. As people participate in physical exercise, sports-related injuries like sprain, tears, and fractures are on the rise. Sports persons and physically active individuals are increasingly opting for orthobiologic therapies in order to speed up recovery, mitigate pain, and enhance functionality. These treatments, including PRP injections and stem cell therapies, are now being utilized to address soft tissue injury, cartilage damage, and joint disease. The demand for faster recovery and enhanced performance is driving the use of orthobiologic solutions by both professional athletes and the recreational fitness enthusiast alike. With sports and fitness remaining central to a healthy lifestyle world-wide, the market for orthobiologics is riding this wave by providing cutting-edge, efficient treatment for musculoskeletal injuries, fueling its expansion and wider integration into the healthcare market. As per an article published by Healio in 2024, Orthopedic-related sports injuries in patients aged at least 65 years were projected to increase by 123% by 2040 and may outpace the number of orthopedic surgeons.

Orthobiologics Market Growth Drivers:

Increased Emphasis on Individualized Medicine

The orthobiologics market is experiencing rapid growth as a result of growing emphasis on personalized medicine. Improved genetic research and diagnostic methods are allowing medical practitioners to customize treatments to the individual patient's unique needs. For musculoskeletal conditions, customized orthobiologic therapies are being created to maximize healing based on variables like a patient's genetic makeup, type of injury, and overall health status. By personalizing biologic therapies, including stem cell therapy and PRP injections, to the patient, these treatments are becoming increasingly more effective in stimulating tissue regeneration and enhancing patient outcomes. This movement towards individualized medicine is also being aided by advances in biomarker discovery and the development of targeted therapeutic approaches, further increasing the accuracy and effectiveness of orthobiologic therapies.

Expanding Reimbursement Coverage and Regulatory Approvals

The market for orthobiologics is being driven considerably by growing reimbursement coverage and more positive regulatory approvals. Increasing numbers of countries are now covering biologic therapies in insurance plans, which is enhancing patient access to advanced therapies. Health systems are also increasingly acknowledging the cost-effectiveness of orthobiologic treatments in the long term because of their ability to minimize the necessity for costly surgeries and lengthy rehabilitation. Regulatory authorities, like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are approving new orthobiologic products, which is further increasing confidence in the market. As healthcare reimbursement policies become more inclusive and supportive of regenerative therapies, increasing numbers of patients are becoming able to access these treatments, which is causing wider adoption. This increased reimbursement coverage and regulatory endorsement are making orthobiologics more financially sustainable for healthcare providers and patients alike, thus promoting the expansion of the market.

Rising Awareness of Musculoskeletal and Joint Health

The growing awareness of joint and musculoskeletal health is driving the demand for orthobiologics. As more individuals recognize the importance of maintaining joint health throughout their lives, there is a rising interest in treatments that promote tissue repair, reduce pain, and improve mobility. Public education campaigns and educational programs are gradually raising awareness of musculoskeletal disorders, including arthritis and tendon damage, and the promise of orthobiologic therapies. This increased awareness is compelling patients to seek alternatives to conventional surgical intervention, resulting in a growing use of biologic treatments like PRP injections and stem cell therapy. In addition, as the world population grows older, the need for efficient and less invasive treatments to treat chronic joint conditions keeps on increasing. Consequently, the increased concentration on joint health is fueling market growth.

Orthobiologics Market Segmentation:

Breakup by Product:

  • Demineralized Bone Matrix
  • Allograft
  • Bone Morphogenetic Protein
  • Viscosupplementation Products
  • Synthetic Bone Substitutes
  • Others

Viscosupplementation products account for the majority of the market share

On the basis of the orthobiologics market research report, viscosupplementation products dominate the market owing to their effectiveness in treating osteoarthritis, particularly of the knee. These substances, which are mostly made of hyaluronic acid, are injected into joints to cushion and lubricate them, thereby minimizing discomfort and enhancing range of motion. As osteoarthritis is highly prevalent, especially in the aging population, the demand for non-surgical and minimally invasive treatment options like viscosupplementation is high. Moreover, viscosupplements offer relief without the significant risks or recovery time associated with joint replacement surgery. Therefore, the ease of administration, growing preference for non-invasive treatments, and increasing awareness of viscosupplementation's benefits contribute to the increasing orthobiologics demand.

Breakup by Type:

  • Knee
  • Ankle
  • Hip
  • Wrist and Shoulder
  • Spine
  • Others

Knee holds the largest share of the industry

The high incidence of degenerative conditions in knees like osteoarthritis and injuries such as ligament tears and cartilage damage is acting as another crucial factor driving the demand for orthobiologics. The knee joint, being a weight-bearing joint, is particularly susceptible to wear and tear over time, leading to significant pain and reduced mobility. Orthobiologic treatments, including viscosupplementation and regenerative therapies, are frequently used to alleviate symptoms and improve function in knee conditions. The high prevalence of knee disorders among both the aging population and athletes, combined with the effectiveness of orthobiologic interventions in reducing pain and promoting healing, is bolstering the market demand.

Breakup by Application:

  • Osteoarthritis and Degenerative Arthritis
  • Spinal Fusion
  • Fracture Recovery
  • Soft Tissue Injuries
  • Maxillofacial and Dental Applications

Osteoarthritis and degenerative arthritis represent the leading market segment

As per the orthobiologics market overview, osteoarthritis and degenerative arthritis are the leading market segments due to their widespread prevalence and impact. These conditions are characterized by the progressive breakdown of joint cartilage, leading to pain, stiffness, and impaired function, particularly in weight-bearing joints like the knees and hips. As the global population ages and more individuals experience these age-related joint issues, the demand for effective treatments grows. Orthobiologic solutions, such as viscosupplementation and regenerative therapies, offer non-surgical options to manage symptoms, improve mobility, and enhance quality of life. Their ability to address the root causes of joint degeneration, combined with a growing preference for MISs is bolstering the orthobiologics market revenue.

Breakup by End User:

  • Hospitals and Ambulatory Centers
  • Research and Academic Institutes
  • Dental Clinics and Facilities
  • Orthopedic Clinics

Hospitals and ambulatory centers exhibit a clear dominance in the market

Hospitals and ambulatory centers are the biggest end user segment due to their comprehensive diagnostic and treatment capabilities. These facilities are equipped with advanced imaging and surgical technologies that enable precise administration of orthobiologic treatments, such as injections and regenerative therapies. Hospitals and ambulatory centers often offer a range of specialized services, including orthopedic surgery and rehabilitation, which integrate seamlessly with ortho-biologic interventions. Furthermore, the ability to manage complex cases and provide immediate medical support enhances the appeal of these settings for both patients and providers. The concentration of skilled healthcare professionals and access to cutting-edge treatments in these facilities are further contributing to the demand for orthobiologics in these settings.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest orthobiologics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for orthobiologics.

The orthobiologics market forecast shows that North America leads the market with its high prevalence of musculoskeletal disorders, such as osteoarthritis, expanding geriatric population, and widespread trends of engaging in high levels of physical activity and sports. Advanced healthcare infrastructure and a high standard of medical care in the U.S. and Canada support the adoption of innovative orthobiologic treatments. Moreover, North America is home to major pharmaceutical and biotech companies that invest heavily in R&D, driving the availability of cutting-edge products. The region's strong regulatory framework and significant healthcare spending further facilitate market growth, making it a leader in the adoption and utilization of orthobiologics.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the orthobiologics industry include Arthrex Inc, Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries Inc., Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Smith & Nephew plc, Stryker Corporation, Terumo Corporation, Wright Medical Group N.V., Zimmer Biomet, etc.
  • The competitive landscape is marked by a dynamic interplay between major pharmaceutical companies, specialized biotech firms, and emerging players. Leading companies with a broad portfolio of products and extensive distribution networks are investing heavily in R&D to innovate and enhance their offerings, particularly in areas like viscosupplementation and regenerative therapies. At the same time, smaller biotech firms are driving competition through specialized, cutting-edge solutions and novel technologies, such as stem cell therapies and advanced growth factors. Additionally, the market is characterized by strategic alliances and mergers among orthobiologics companies, which enhance market reach and capabilities. Besides this, regulatory approvals and clinical advancements significantly influence market dynamics, making the industry highly competitive and continuously evolving.

Key Questions Answered in This Report:

  • How has the global orthobiologics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global orthobiologics market?
  • What is the impact of each driver, restraint, and opportunity on the global orthobiologics market?
  • What are the key regional markets?
  • Which countries represent the most attractive orthobiologics market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the orthobiologics market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the orthobiologics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the orthobiologics market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the orthobiologics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global orthobiologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Orthobiologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Demineralized Bone Matrix
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Allograft
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bone Morphogenetic Protein
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Viscosupplementation Products
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Synthetic Bone Substitutes
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Knee
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ankle
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Hip
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Wrist and Shoulder
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Spine
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Osteoarthritis and Degenerative Arthritis
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Spinal Fusion
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Fracture Recovery
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Soft Tissue Injuries
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Maxillofacial and Dental Applications
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Ambulatory Centers
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research and Academic Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Dental Clinics and Facilities
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Orthopedic Clinics
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Arthrex Inc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 SWOT Analysis
    • 15.3.2 Globus Medical Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Integra LifeSciences
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Johnson & Johnson
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Medline Industries Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 Medtronic plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 NuVasive Inc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Orthofix Medical Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Smith & Nephew plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Stryker Corporation
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Terumo Corporation
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Wright Medical Group N.V.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 SWOT Analysis
    • 15.3.13 Zimmer Biomet
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Orthobiologics Market: Major Drivers and Challenges
  • Figure 2: Global: Orthobiologics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Orthobiologics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Orthobiologics Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Orthobiologics Market: Breakup by Type (in %), 2024
  • Figure 6: Global: Orthobiologics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Orthobiologics Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Orthobiologics Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Orthobiologics (Demineralized Bone Matrix) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Orthobiologics (Demineralized Bone Matrix) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Orthobiologics (Allograft) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Orthobiologics (Allograft) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Orthobiologics (Bone Morphogenetic Protein) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Orthobiologics (Bone Morphogenetic Protein) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Orthobiologics (Viscosupplementation Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Orthobiologics (Viscosupplementation Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Orthobiologics (Synthetic Bone Substitutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Orthobiologics (Synthetic Bone Substitutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Orthobiologics (Other Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Orthobiologics (Other Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Orthobiologics (Knee) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Orthobiologics (Knee) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Orthobiologics (Ankle) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Orthobiologics (Ankle) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Orthobiologics (Hip) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Orthobiologics (Hip) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Orthobiologics (Wrist and Shoulder) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Orthobiologics (Wrist and Shoulder) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Orthobiologics (Spine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Orthobiologics (Spine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Orthobiologics (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Orthobiologics (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Orthobiologics (Osteoarthritis and Degenerative Arthritis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Orthobiologics (Osteoarthritis and Degenerative Arthritis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Orthobiologics (Spinal Fusion) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Orthobiologics (Spinal Fusion) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Orthobiologics (Fracture Recovery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Orthobiologics (Fracture Recovery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Orthobiologics (Soft Tissue Injuries) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Orthobiologics (Soft Tissue Injuries) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Orthobiologics (Maxillofacial and Dental Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Orthobiologics (Maxillofacial and Dental Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Orthobiologics (Hospitals and Ambulatory Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Orthobiologics (Hospitals and Ambulatory Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Orthobiologics (Research and Academic Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Orthobiologics (Research and Academic Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Global: Orthobiologics (Dental Clinics and Facilities) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Global: Orthobiologics (Dental Clinics and Facilities) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Global: Orthobiologics (Orthopedic Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Global: Orthobiologics (Orthopedic Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: North America: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: North America: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: United States: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: United States: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Canada: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Canada: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Asia-Pacific: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Asia-Pacific: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: China: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: China: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Japan: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Japan: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: India: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: India: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: South Korea: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: South Korea: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Australia: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Australia: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Indonesia: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Indonesia: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Europe: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Europe: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Germany: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Germany: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: France: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: France: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: United Kingdom: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: United Kingdom: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Italy: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Italy: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Spain: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Spain: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Russia: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Russia: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Others: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Others: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Latin America: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Latin America: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Brazil: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Brazil: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Mexico: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Mexico: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 95: Others: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 96: Others: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 97: Middle East and Africa: Orthobiologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 98: Middle East and Africa: Orthobiologics Market: Breakup by Country (in %), 2024
  • Figure 99: Middle East and Africa: Orthobiologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 100: Global: Orthobiologics Industry: SWOT Analysis
  • Figure 101: Global: Orthobiologics Industry: Value Chain Analysis
  • Figure 102: Global: Orthobiologics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Orthobiologics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Orthobiologics Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Orthobiologics Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 4: Global: Orthobiologics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Orthobiologics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Orthobiologics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Orthobiologics Market: Competitive Structure
  • Table 8: Global: Orthobiologics Market: Key Players